J M Pagel

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 111:2261-8. 2008
  2. pmc Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia
    John M Pagel
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Cancer Res 69:185-92. 2009
  3. doi request reprint Radioimmunotherapeutic approaches for leukemia: the past, present and future
    J M Pagel
    Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Cytotherapy 10:13-20. 2008
  4. ncbi request reprint Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas
    John M Pagel
    Fred Hutchinson Cancer Research Center, University of Washington, and Aletheon Pharmaceuticals, Inc, Seattle, Washington 98109, USA
    Cancer Res 67:5921-8. 2007
  5. pmc A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 113:4903-13. 2009
  6. pmc Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 118:703-11. 2011
  7. pmc 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
    John M Pagel
    Division of Clinical Research, Fred Hutchinson Cancer Research Center D5 380, 1100 Fairview Ave N, PO Box 19024, Seattle, WA 98109, USA
    Blood 107:2184-91. 2006
  8. pmc Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
    John M Pagel
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 114:5444-53. 2009
  9. ncbi request reprint Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas
    John M Pagel
    Fred Hutchinson Cancer Research Center Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 11:4857-66. 2005
  10. ncbi request reprint Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas
    John M Pagel
    Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle 98109, USA
    Blood 101:2340-8. 2003

Collaborators

Detail Information

Publications42

  1. pmc Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 111:2261-8. 2008
    ..These data suggest that anti-CD45 PRIT using an anti-CD45-SA conjugate in a syngeneic murine model of disseminated leukemia may be more effective and less toxic than directly labeled monoclonal antibodies...
  2. pmc Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia
    John M Pagel
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Cancer Res 69:185-92. 2009
    ..These data suggest that pretargeted methods for delivering RIT may be superior to conventional RIT when targeting CD45 for the treatment of leukemia and may allow for the intensification of therapy, while minimizing toxicities...
  3. doi request reprint Radioimmunotherapeutic approaches for leukemia: the past, present and future
    J M Pagel
    Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Cytotherapy 10:13-20. 2008
    ..Discussion of pre-clinical studies are limited to those that offer insights into future directions for clinical RIT studies of leukemia...
  4. ncbi request reprint Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas
    John M Pagel
    Fred Hutchinson Cancer Research Center, University of Washington, and Aletheon Pharmaceuticals, Inc, Seattle, Washington 98109, USA
    Cancer Res 67:5921-8. 2007
    ..Improvements in tumor-to-normal organ ratios of radioactivity cannot be achieved using directly labeled Abs in combination but may be afforded by novel pretargeting methods...
  5. pmc A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 113:4903-13. 2009
    ..We hypothesize that clinical implementation of pretargeted RIT methods will provide a meaningful prolongation of survival for patients with relapsed lymphomas compared with currently available treatment strategies...
  6. pmc Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 118:703-11. 2011
    ..These data suggest that anti-CD45 PRIT using an α-emitting radionuclide may be highly effective and minimally toxic for treatment of acute myeloid leukemia...
  7. pmc 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
    John M Pagel
    Division of Clinical Research, Fred Hutchinson Cancer Research Center D5 380, 1100 Fairview Ave N, PO Box 19024, Seattle, WA 98109, USA
    Blood 107:2184-91. 2006
    ..39-1.08; P = .09). The addition of targeted hematopoietic irradiation to conventional BU/CY is feasible and well tolerated, and phase 2 results are sufficiently encouraging to warrant further study...
  8. pmc Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
    John M Pagel
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 114:5444-53. 2009
    ..This study was registered at www.clinicaltrials.gov as #NCT00008177...
  9. ncbi request reprint Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas
    John M Pagel
    Fred Hutchinson Cancer Research Center Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 11:4857-66. 2005
    ..Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is a transmembrane enzyme critical for the biosynthesis of phosphoglycerides whose product, phosphatidic acid, plays a key role in raf and AKT/mTor-mediated signal transduction...
  10. ncbi request reprint Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas
    John M Pagel
    Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle 98109, USA
    Blood 101:2340-8. 2003
    ..These lymphoma xenograft data suggest that pretargeted radioimmunotherapy using either anti-CD20 or anti-CD45 conjugates is highly effective and minimally toxic...
  11. pmc Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab
    Ajay K Gopal
    Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98195, USA
    Blood 112:830-5. 2008
    ....
  12. ncbi request reprint Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts
    Krishnan Subbiah
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Nucl Med 44:437-45. 2003
    ..This study compared the immunoscintigraphy, toxicity, and therapeutic efficacy of pretargeted RIT with conventional RIT using an anti-CD20 antibody...
  13. pmc Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas
    John M Pagel
    Fred Hutchinson Cancer Research Center, and the Department of Medicine, the Univerisity of Washington, Seattle, WA 98109, USA
    Blood 108:328-36. 2006
    ..More than 90% of lymphomabearing mice could be cured with minimal toxicity using either reagent followed by 1200 muCi (44.4 MBq) 90Y-DOTA-biotin...
  14. ncbi request reprint Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism
    Ajay K Gopal
    Seattle Cancer Care Alliance, Mailstop G6 800, Rm 6802, University of Washington, 825 Eastlake Ave E, Seattle, 98109, USA
    Blood 103:3516-20. 2004
    ..05). These results establish the efficacy of 4HPR/rituximab combinations, confirm their caspase-mediated mechanism of action, and offer the potential for disease control with minimal toxicity for patients with B-cell malignancies...
  15. pmc Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants
    D Scott Wilbur
    Department of Radiation Oncology, University of Washington, Seattle, Washington 98105, USA
    Bioconjug Chem 21:1225-38. 2010
    ..While the reasons for the higher blood and liver concentrations are unknown, the differences in the galactose structures of the clearance agents 1 and 2 may play a role...
  16. ncbi request reprint High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma
    Ajay K Gopal
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98195, USA
    J Clin Oncol 25:1396-402. 2007
    ..Myeloablative anti-CD20 radioimmunotherapy (RIT) can deliver curative radiation doses to tumor sites while limiting exposure to normal organs and may be particularly suited for older adults requiring high-dose therapy...
  17. pmc Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas
    Anastasia Pantelias
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Blood 109:4980-7. 2007
    ..This study highlights the importance of screening the antigenic expression on lymphomas to select the optimal reagent for PRIT...
  18. pmc Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium
    Ajay K Gopal
    University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Leuk Lymphoma 51:1523-9. 2010
    ..5%) and grade 4 non-hematologic adverse events (n = 2) were rare, with no treatment-related deaths. GCD(R) is a safe and effective outpatient regimen for relapsed lymphoma, and successfully mobilizes PBSCs...
  19. ncbi request reprint A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies
    Yukang Lin
    The Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Cancer Res 66:3884-92. 2006
    ..These promising results have prompted large-scale cGMP production of the BC8 fusion protein for clinical trials to be conducted in patients with hematologic malignancies...
  20. pmc Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211
    Hirohisa Nakamae
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, USA
    Cancer Res 69:2408-15. 2009
    ..The data suggest that smaller quantities of (211)At-labeled anti-CD45 antibody are sufficient to achieve myelosuppression and myeloablation with less nonhematologic toxicity compared with (213)Bi-labeled antibody...
  21. pmc High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience
    Ajay K Gopal
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington 98195, USA
    Cancer 113:1344-50. 2008
    ..We explored the utility of HDT and ASCT for chemoresistant HL because there are few established therapies for these patients...
  22. pmc 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma
    Ajay K Gopal
    Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, USA
    Blood 113:5905-10. 2009
    ..5 days, P < .001) compared with controls. These data indicate that the high CD45 expression of T-NHL allows reliable tumor targeting and disease control supporting anti-CD45 RIT for T-NHL patients...
  23. ncbi request reprint Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy
    Ajay K Gopal
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington 98195, USA
    Biol Blood Marrow Transplant 12:697-702. 2006
    ..The rationale for incorporation of radioimmunotherapy into reduced intensity allogeneic transplantation regimens for non-Hodgkin lymphoma is discussed, as are current study designs, preliminary results, and future directions...
  24. ncbi request reprint Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older
    Herschel Wallen
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Ave N, D3 100, Seattle, WA 98109, USA
    J Clin Oncol 23:3439-46. 2005
    ..To evaluate outcomes of ablative allogeneic hematopoietic cell transplantation (HCT) in older patients with hematologic malignancies...
  25. ncbi request reprint The use of radioimmunoconjugates in stem cell transplantation
    J M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Bone Marrow Transplant 29:807-16. 2002
    ..In this report we review clinical studies that have incorporated myeloablative doses of targeted radiation using radiolabeled antibodies in conjunction with stem cell transplant regimens...
  26. pmc Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission
    R B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leukemia 24:1276-82. 2010
    ..16 (0.52-2.61), P=0.71). These data indicate that URD HCT can provide long-term survival for CR1 AML; outcomes for 10/10 URD HCT, and possibly 9/10 URD HCT, suggest that this modality should be considered in the absence of a suitable MRD...
  27. ncbi request reprint The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma
    R N Pham
    Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA
    Bone Marrow Transplant 40:1039-44. 2007
    ..52, P=0.03), chemoresistance (HR=1.82, P=0.02), > or =2 prior therapies (HR=1.8, P=0.03) and prior radiation (HR=1.99, P=0.003). These data suggest that the histologic grade of FL does not impact PFS or relapse following HDT and ASCT...
  28. ncbi request reprint Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model
    Eneida R Nemecek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Clin Cancer Res 11:787-94. 2005
    ..We evaluated the organ localization of yttrium-90-labeled anti-CD45 ((90)Y-anti-CD45) antibody in macaques, a model that had previously predicted iodine-131-labeled anti-CD45 ((131)I-anti-CD45) antibody biodistribution in humans...
  29. pmc Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
    Brian G Till
    Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 112:2261-71. 2008
    ..These results show the safety, feasibility, and potential antitumor activity of adoptive T-cell therapy using this approach. This trial was registered at www.clinicaltrials.gov as #NCT00012207...
  30. pmc Pretargeted radioimmunotherapy for hematologic and other malignancies
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Biother Radiopharm 25:125-42. 2010
    ..With continued research, PRIT-based treatment strategies promise to become cornerstones to improved outcomes for cancer patients despite their complexities...
  31. pmc Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Oncol 29:1190-7. 2011
    ..Hitherto, little attention has been given to the prognostic impact of pretransplantation minimal residual disease (MRD)...
  32. pmc Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 111:4813-6. 2008
    ..These data suggest that further study of this antibody combination for clinical use in AML is warranted...
  33. pmc Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 114:1226-35. 2009
    ..These results support proceeding to anti-CD45 PRIT clinical trials for patients with both leukemia and lymphoma...
  34. ncbi request reprint Pretargeted radioimmunotherapy for B-cell lymphomas
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 13:5598s-5603s. 2007
    ..We are optimistic that this novel approach will provide a meaningful prolongation of survival for patients with relapsed or refractory lymphomas...
  35. pmc Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma
    Brian G Till
    Clinical Research Division of Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leuk Lymphoma 49:1062-73. 2008
    ....
  36. pmc HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category
    Ann Woolfrey
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 16:1382-7. 2010
    ..However, for patients with intermediate-risk disease, transplantation with peripheral blood from a 10/10 MUD is associated with lower survival than an MSD...
  37. ncbi request reprint Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia
    Daniella M B Kerbauy
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 11:713-20. 2005
    ..D. Anderson prognostic score. The data suggest that patients with few or no comorbidities and those who undergo transplantation earlier in the disease course have the highest probability of successful outcome after allogeneic HCT...
  38. doi request reprint Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantation
    Jaideep Shenoi
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine from the University of Washington, Seattle, Washington, USA
    Curr Opin Oncol 22:143-9. 2010
    ....
  39. ncbi request reprint The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation
    Grant E Keeney
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA
    Leuk Lymphoma 48:1961-7. 2007
    ..82, p = 0.03) after adjusting for FLIPI. These data suggest that the FLIPI and select non-FLIPI factors after adjustment for the FLIPI are associated with survival in FL patients undergoing ASCT...
  40. doi request reprint Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies
    Eneida R Nemecek
    Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA
    Cancer Biother Radiopharm 23:181-91. 2008
    ..We examined an "extracorporeal adsorption therapy" (ECAT) method to remove circulating unbound radioimmunoconjugate and improve the ratios of radiation delivered to B-cells in a macaque model...
  41. ncbi request reprint Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines
    Shao Xu Ying
    Shanghai Sixth Hospital, Shanghai Jiaotong University, Shanghai, China
    Leuk Lymphoma 48:1003-14. 2007
    ..These studies add further information to the regulation of programmed cell death in leukemic cells that have to be considered when designing therapeutic strategies...
  42. ncbi request reprint Therapeutic use of Rituximab for sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease)
    John M Pagel
    Am J Hematol 82:1121-2. 2007

Research Grants3

  1. Radioimmunotherapy of CD20+ Lymphomas & CD45+Leukemias
    JOHN PAGEL; Fiscal Year: 2007
    ..abstract_text> ..
  2. Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
    John M Pagel; Fiscal Year: 2010
    ..We anticipate that these approaches will cure more patients and cause fewer toxicities than currently available therapies. ..